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Background. Dialysis patients require special consideration
regarding analgesics, given their altered pharmacokinetic and
pharmacodynamic profiles and increased potential for adverse
reactions.
Methods. Analgesic prescription patterns were investigated
using data from the Dialysis Outcomes and Practice Patterns
Study (DOPPS), with 3749 patients in 142 United States facili-
ties studied between May 1996 and September 2001.
Results. The proportion of patients prescribed any anal-
gesic decreased from 30.2% to 24.3%; narcotic prescriptions
decreased from 18.0% to 14.9%. The most commonly pre-
scribed narcotics were propoxyphene/acetaminophen combina-
tions (47.2%). Combinations containing acetaminophen were
prescribed concurrently for 84.1% of patients on narcotics.
About one half of prescriptions for narcotics, acetaminophen,
and cyclooxygenase-2 (COX-2) agents were for 12 months
or more; one half of prescriptions for nonsteroidal anti-
inflammatory drugs (NSAIDs) were for 8 months or more. The
proportion of patients prescribed analgesics varied by facility
(mean ± SD = 27.9% ± 18.9% for all analgesics, range 0% to
89.3%). Analgesic prescription was more likely among the el-
derly, women, and patients with cardiovascular disease (other
than coronary artery disease or congestive heart failure), lung
and psychiatric disease, cancer (other than skin), and recur-
rent cellulitis. Patients prescribed laxatives were almost twice
as likely to be on a narcotic (odds ratio = 1.95, P < 0.0001).
Analgesic prescription did not correlate with loss of residual
renal function or hospitalization for a gastrointestinal disorder.
Three-quarters of patients reporting moderate to very severe
pain were not prescribed analgesics. Furthermore, 74% of pa-
tients with pain that interfered with work had no analgesic pre-
scription.
Conclusion. Dialysis patients and providers may benefit from
both refinement of existing guidelines and a renewed under-
standing regarding appropriate prescription of analgesics.
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Patients with chronic kidney disease (CKD) and end-
stage renal disease (ESRD) may suffer from chronic pain
due to advanced bone disease, neuropathies, and surgery.
Dialysis patients require special consideration with re-
spect to analgesic use. Aspirin has beneficial effects as an
anti-platelet agent [1] and is relatively safe in renal failure.
However, alterations in pharmacokinetic and pharma-
codynamic properties of narcotic and nonnarcotic anal-
gesics in patients with CKD and ESRD may result in
increased potential for adverse effects [2–10]. Clearance
may be reduced for those agents and their metabolites
that are primarily excreted by the kidney. Clinical practice
guidelines are available for pain management in patients
with cancer [11], but there are no such guidelines for pa-
tients with kidney disease. The National Kidney Founda-
tion suggests that use of nonsteroidal anti-inflammatory
drugs (NSAIDs) should be discouraged in patients with
kidney disease [12], and a recent review recommended
the use of a step-wise approach to pain management in
CKD and ESRD, as promulgated by the World Health
Organization [10, 11]. On the other hand, data from
dialysis patients [13] and populations other than those
on hemodialysis suggest that pain is often undertreated
and that analgesics are underprescribed [14–17]. Among
dialysis patients, this can result in reduced quality of
life because of pain, insomnia, and high unemployment
[18–21].
Little detailed information is available about the use
of analgesics in patients undergoing dialysis. The United
States Renal Data System (USRDS) reported a compi-
lation of data in 1998 pertaining to medication use in
dialysis outpatients [22], showing that, overall, 12% of
hemodialysis patients and 9% of peritoneal dialysis pa-
tients were prescribed some form of analgesic product.
More recent studies have shown that up to 35% of pa-
tients in individual outpatient dialysis centers were pre-
scribed analgesics, although it was unclear what types of
analgesics were used and for how long they were pre-
scribed in each patient [23, 24]. The present investigation
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uses data from the Dialysis Outcomes and Practice Pat-
terns Study (DOPPS) to evaluate analgesic prescription
practices in greater detail, including choice of narcotic
and nonnarcotic agents, duration of use, patterns of use
among dialysis facilities, patient characteristics associated
with analgesic prescription, complications of analgesics
(with respect to hospitalizations due to gastrointestinal
complications, loss of kidney function, and constipation),
and patient self-reported pain levels associated with anal-
gesic prescription.
METHODS
The DOPPS is a prospective, observational study
of hemodialysis patients and facilities in France, Ger-
many, Italy, Japan, Spain, the United Kingdom, and the
United States [25, 26]. For this paper, only data from
the United States (US-DOPPS) were used. Briefly, the
major goal of the DOPPS is to investigate the impact
of hemodialysis practice patterns on patient outcomes,
particularly on mortality, hospitalization, vascular ac-
cess survival, and quality of life. In the US-DOPPS,
a stratified random sample of chronic dialysis facilities
was first selected. Within each selected facility, a cen-
sus was taken of prevalent hemodialysis patients older
than 17 years, from which 20 to 40 patients were ran-
domly chosen, using an algorithm based on the total
sample size of the facility. Data were collected every
4 months for each participating patient using survey
questionnaires administered by a study coordinator at
each facility. Data include patient demographic charac-
teristics, medical histories, laboratory values, outcomes
(including quality of life and gastrointestinal hospitaliza-
tions), and prescribed over-the-counter and prescription
drugs. Data were collected longitudinally between 1996
and 2001 in the United States national random sample of
142 facilities; on average, about 3000 patients were partic-
ipating at any time. The database was maintained at the
central coordination center and subject to programmatic
checks.
Using a computerized drug database, drug data were
classified and categorized down to specific brand, dosage
form, and strength, while allowing categorization into one
of several drug classes. The names of all prescribed over-
the-counter and prescription analgesics were recorded
for each patient on entry into the study and at 4-month in-
tervals thereafter. The actual consumption of prescribed
medicines was not recorded. Data for aspirin were ex-
cluded from this analysis, as the high number of patients
on very low doses of aspirin made it clear that, in the ma-
jority of cases, this drug was used as an antiplatelet ag-
gregation agent and not as an analgesic. Data pertaining
to analgesic prescription during any periods of hospital-
ization were not included.
Statistical methods
Baseline patient demographics, comorbidities, and
analgesic use were investigated using descriptive statis-
tics. Facility variation was examined, using a mixed-model
logistic regression that adjusted for comorbidities and as-
sumed a binomial distribution of analgesic use with the
same probability of prescription at each facility [27].
For each analgesic group, a Kaplan-Meier estimate was
used to examine the duration of use. Analgesic use at
consecutive follow-up visits was assumed to reflect con-
tinuous use between visits. Duration of analgesic use was
defined as the time from a previous visit with documented
analgesic prescription to a visit when there was no longer
documented analgesic prescription.
Logistic regression analysis was used to examine
associations between analgesic use and both patient
demographics and comorbid conditions. Logistic regres-
sion also was employed to investigate the relationship
between use of narcotic analgesics and laxatives. Time
from study entry to first gastrointestinal hospitalization
(defined by a diagnosis of gastrointestinal bleed or pep-
tic ulcer disease or by an upper endoscopy or gastric
surgery/resection procedure) and time from study entry
to loss of residual kidney function (defined as a decline in
urine output from ≥200 mL/day to <200 mL/day) were
examined using Cox proportional hazards models [28],
with analgesic prescription entered as a time-varying co-
variate. Associations between analgesic prescription and
patient self-reported pain scores, taken from the SF-36
Quality of Life questionnaire [29], were assessed. All data
analyses were conducted using SAS version 8.2 (SAS In-
stitute, Cary, NC, USA).
RESULTS
Data from 142 facilities and a prevalent sample of
3749 United States hemodialysis patients were available
for analysis. Patient demographics are shown in Table 1.
Longitudinal data on analgesic prescription prevalence
between May 1996 and September 2001 are shown in
Figure 1. The rise in prescription of cyclooxygenase-
2 (COX-2) inhibitors during 1999 and 2000 coincides
with declines in prescriptions of both acetaminophen and
NSAIDs. Information on prescriptions of combinations
of analgesics is given in Table 2 for two time points, May
1997 (pre-COX-2) and September 2000 (post-COX-2).
The total proportion of patients prescribed any analgesic
decreased from 30.2% to 24.3% between these two time
points, with a reduction in narcotic analgesic prescription
from 18.0% to 14.9%. Prescription of NSAIDs decreased
from 6.4% to 2.3%, coincident with the availability of
COX-2 inhibitors, which increased from 0% to 4.9%.
Based on data from study entry for each patient,
the most commonly prescribed narcotics were combi-
nations of propoxyphene and acetaminophen (47.2%).
The narcotics most frequently prescribed as single agents
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Table 1. Descriptive statistics for a prevalent cross-section of patients
at baseline
Characteristic % or Mean (SD)
Age years 60.6 (15.5)
Male % 53.0
Race/ethnicity %
Caucasian 53.0
African American 38.2
Asian 3.8
Native American 1.3
Other 3.7
Time on dialysis years 3.4 (3.8)
Comorbidities %
Coronary artery disease 50.4
Congestive heart failure 46.1
Other cardiac disease 36.6
Hypertension (primary or contributing) 84.1
Cerebrovascular disease 18.3
Peripheral vascular disease 26.2
Diabetes (primary or contributing) 46.2
Lung disease 13.0
Cancer (other than skin) 9.7
HIV/AIDS 1.1
Gastrointestinal bleed 10.0
Neurologic disease 12.5
Psychiatric disease 24.1
Recurrent cellulitis 11.3
were propoxyphene (3.5%), hydrocodone (2.5%), oxy-
codone (2.3%), and morphine (2.2%). Propoxyphene, ei-
ther alone or in combination, was therefore prescribed
for 50.7% of patients who were prescribed narcotic
analgesics. In addition, acetaminophen-containing com-
binations were prescribed for 84.1% of patients with
prescriptions for narcotic analgesics. Among patients
prescribed NSAIDs, the most common prescriptions
were ibuprofen (33%), naproxen (16.8%), and in-
domethacin (12.5%).
Figure 2 shows the duration of analgesic use for patients
who began using an analgesic during the study. This figure
is helpful in describing the use of analgesics in the popu-
lation as long term or short term. About half of prescrip-
tions for narcotics, acetaminophen, and COX-2 agents
were for periods of 12 months or more, and about 25%
were for more than 28 months. NSAIDs were prescribed
for shorter durations. About half of NSAID prescriptions
were for periods of 8 months or more, while about 25%
were for more than 16 months.
Associations between analgesic use and self-reported
pain indices at baseline are indicated in Table 3. Using
the physical bodily pain subscale results from the SF-36,
which can range from 0 (worst pain) to 100 (no pain), the
average score was 60.8 for patients not on analgesics and
48.5 for those prescribed an analgesic, indicating worse
pain for those on analgesics. Patients were asked two
questions about their pain and pain control. In question
1, “How much bodily pain have you had in the past four
weeks?” possible responses were “none,” “very mild,”
“mild,” “moderate,” “severe,” and “very severe.” Re-
sponses were grouped for the “none to mild” categories
and for the “moderate to very severe” categories. Table 3
indicates that 73.8% of patients who reported moderate
to very severe pain were prescribed no analgesics. For
question 2, “During the last four weeks, how much did
the pain interfere with your normal work (including both
work outside the home and housework)?” Possible re-
sponses were “not at all,” “slightly,” “moderately,” “quite
a bit,” and “extremely.” Responses were grouped for the
“not at all to slightly” categories and for the “moderately
to extremely” categories. Some 74.4% of patients report-
ing moderate to extreme interference had no analgesic
prescription. There were more narcotic prescriptions in
the “moderate to very severe” versus “none to mild” cat-
egories (17.2% vs. 9.3%) and “moderately to extremely”
versus “none at all to slightly” categories (16.4% vs. 9.3%)
for questions 1 and 2, respectively.
Substantial facility variation was found in analgesic
prescription practices (Fig. 3). From the cross-section of
data on September 2000, facilities, on average, prescribed
analgesics for 27.9% of their patients, but individual fa-
cility percentages of patients on analgesics ranged from
0% to 89.3%. This level of facility variation, when ad-
justed for comorbidities, is more than would be expected
by chance alone (P < 0.0001 for each type of analgesic,
as well as the use of any analgesic). It appears that these
facility differences are due to differences in facility pre-
scription practices. In addition, a statistically significant
(P = 0.002), but only modestly predictive (r = 0.26) posi-
tive association was found between facility-level narcotic
and nonnarcotic analgesic use, indicating that facilities
prescribing more nonnarcotic analgesics were inclined to
prescribe more narcotics as well.
A summary of selected variables associated with the
prescription of analgesics is shown in Table 4. Increased
time on dialysis was positively correlated with the use
of all analgesics. Prescription of any analgesic was sig-
nificantly positively associated with increased age, fe-
male gender, cardiovascular disease [other than coronary
artery disease (CAD) or congestive heart failure (CHF)],
lung disease, cancer (other than skin), psychiatric disease,
and recurrent cellulitis. Narcotics were more commonly
prescribed for women, patients with CAD, cardiovascular
disease (other than CHF and CAD), lung disease, psychi-
atric illness, and recurrent cellulitis. Among the nonnar-
cotic agents, NSAIDs were more commonly prescribed
for patients with CAD, lung disease, and for African
American patients. Acetaminophen was prescribed more
often in older patients and in those with cerebrovascu-
lar disease, cardiovascular disease (other than CAD and
CHF), and neurologic disorder. Prescription of COX-2
agents was not significantly associated with any demo-
graphic or comorbidity variables, possibly because of the
small number of patients on COX-2 inhibitors. Patients
on NSAIDS, acetaminophen, or COX-2 inhibitors were
all more likely to also be on a narcotic analgesic.
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Table 2. Point prevalences of analgesic use
Number of Patients
Analgesic medication May 1997 September 2000
or combination (N = 2988) (N = 2476)
Any analgesic 901 (30.2%) 602 (24.3%)
Any narcotic 538 (18.0%) 368 (14.9%)
Any nonsteroidal anti-inflammatory 191 (6.4%) 56 (2.3%)
drugs (NSAIDs)
Any acetaminophen 332 (11.1%) 157 (6.3%)
Any cyclooxygenase (COX-2) 0 (0.0%) 121 (4.9%)
Narcotic + acetaminophen 81 (2.7%) 42 (1.7%)
Narcotic + COX-2 0 (0.0%) 30 (1.2%)
Narcotic + NSAIDs 58 (1.9%) 14 (0.6%)
Acetaminophen + COX-2 0 (0.0%) 13 (0.5%)
Acetaminophen + NSAIDs 36 (1.2%) 7 (0.3%)
COX-2 + NSAIDs 0 (0.0%) 4 (0.2%)
Potential complications of analgesic use were also in-
vestigated. Laxative prescription was used as a surrogate
marker for analgesic-associated constipation. Patients
prescribed laxatives were more likely to be on narcotics
(OR = 1.95, P < 0.001), acetaminophen (OR = 1.76, P <
0.0001), and NSAIDs (OR = 1.47, P = 0.0033). There was
no significant correlation between laxative use and pre-
scription of COX-2 agents. No significant correlation was
found between the use of analgesics and loss of residual
kidney function (P = 0.79) or hospitalization for a gas-
trointestinal disorder (P = 0.54). This lack of significance
could possibly be due to the number of events seen; for
example, gastrointestinal hospitalizations made up 5.7%
of all first hospitalizations.
DISCUSSION
In May of 1997, nonnarcotic analgesics, either alone
or in combination, were prescribed for approximately
18% of the study population. Although information was
collected about over-the-counter analgesics, this num-
ber may be an underestimate of actual analgesics con-
sumed, because the data were dependent upon patient
recollection, as opposed to definitive counts. The number
of intravenous drug abusers in the study population was
unknown, which may also affect usage because clinicians
could be less inclined to prescribe analgesics in those cir-
cumstances. In comparison, data collected by the USRDS
in 1996 to 1997 showed that only about 6.8% of hemodial-
ysis patients were prescribed NSAIDs or other nonnar-
cotic analgesics; it was not clear, however, if those data
included patients who may have been prescribed both a
narcotic and a nonnarcotic agent [22]. NSAIDs were the
major type of nonnarcotic analgesic prescribed for dialy-
sis patients in the current study—notably ibuprofen, fol-
lowed by naproxen and indomethacin. Of patients taking
narcotic analgesics, most were prescribed propoxyphene
alone or in a combination product with acetaminophen
(50.5% of the time).
There are several limitations to this study. First, combi-
nation products do not permit titration of the individual
components. Given the large proportion of patients on
combination products, ascertaining titration of the dose
for individual patients is impossible. Further, determin-
ing the optimal dose for a stated level of self-reported
pain is difficult even under ideal circumstances. Finally,
the data reflect prescription, not actual consumption, of
analgesics, a factor that may be significantly influenced by
adherence. Because data were collected approximately
every 4 months, it is possible that some patients received
shorter courses of analgesic prescription between those
time points. In this instance, there would have been an
underestimation of analgesic prescription. Additionally,
patients who may have received two short-duration pre-
scriptions for analgesics just prior to two successive data
collection points would have been recorded as having
received at least a 4-month prescription. Such an oc-
currence would have led to an overestimation of anal-
gesic prescription. The net effect of these circumstances is
uncertain.
Based on patient self-reported pain status, analgesics
may be underprescribed among hemodialysis patients in
the United States. Clearly, these reports are not exter-
nally validated by an assessment regarding which pa-
tients should have been prescribed analgesics but were
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Table 3. Self-reported pain and the use of analgesics at baseline
% of Patients
Pain interferes with
normal work (inside and
Pain in past 4 weeks outside the house)
None to Moderate to Not at all Moderately
Medication mild very severe to slightly to extremely
Narcotic 9.3 17.2 9.3 16.4
Acetaminophen 5.4 5.3 5.0 5.5
Nonsteroidal anti- 2.5 3.4 2.5 3.4
inflammatory
drugs (NSAIDs)
Cyclooxygenase-2 0.5 0.3 0.4 0.3
(COX-2)
None 82.3 73.8 82.8 74.4
Total 100.0 100.0 100.0 100.0
not. Nevertheless, the data suggest that more attention
should be paid to pain. The fact that significant pain is of-
ten present has previously been documented in dialysis
patients and other populations, with significant repercus-
sions [13–21]. For patients with end-stage renal disease
(ESRD), quality-of-life studies have shown high scores
for bodily pain and other measures compared with the
general population, leading to reduced employment rates
and physical functioning [13, 21]. Diabetic hemodialysis
patients are at increased risk for insomnia [19], which it-
self may reduce quality of life and has been associated
with increased bodily pain [20]. While these studies were
not designed to examine the appropriateness of analgesic
use and pain control, nevertheless, there is a clear picture
of high levels of pain in dialysis patients, with the assump-
tion of inadequate analgesia. There was a positive asso-
ciation of analgesic use with psychiatric disorders, which
includes depression. Chronic pain frequently can lead to
depression, and it was demonstrated that almost 50% of
peritoneal dialysis patients in one cohort suffered from
clinical depression [30].
Of interest is the change in analgesic prescription prac-
tice patterns over time, with a general trend toward
lower use. The influence of new agents is evidenced
by the switch in prescription from acetaminophen and
NSAIDs to COX-2 agents, which became available in
1999. The duration of analgesic prescription was long,
with about half of the patients taking analgesics for
a year or more. Long-term (weeks to months) treat-
ment might be quite appropriate for chronic pain but
would be less so for acute situations. Other studies have
found that hemodialysis patients have a high incidence
(>60%) of constipation; this has been linked to various
factors, including long-term use of certain medications
such as potassium-binding resin [31]. Results from the
present study demonstrated a significant correlation be-
tween laxative use and the prescription of narcotics, ac-
etaminophen, and NSAIDs, which may validate previous
findings.
While this study was unable to capture data pertaining
to side effects from analgesics, the potential for adverse
reactions is high. NSAIDs have many possible adverse ef-
fects, including compromise of any residual kidney func-
tion. It is becoming increasingly clear that COX-2 agents
also have the potential to damage kidney function [32–
34]. Although results from the present study did not
demonstrate an effect of NSAID prescription on resid-
ual kidney function, such function is an independent risk
factor associated with morbidity and mortality in peri-
toneal dialysis patients [35]; whether loss of residual kid-
ney function is a risk factor for mortality in hemodialysis
is uncertain. Narcotic agents, too, have inherent toxici-
ties. Propoxyphene is metabolized to norpropoxyphene,
which may produce cardiotoxicity as well as central ner-
vous system and respiratory depression in dialysis pa-
tients [5]. Other narcotic agent toxicities include seizures,
constipation, physical and psychologic dependence, and
interactions with other drugs.
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(based on data from September 2000). The
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cility variation was significantly (P < 0.0001)
greater than one would expect by chance.
Table 4. Variables associated with the use of analgesics
Nonsteroidal
anti-inflammatory Cyclooxygenase-2
Any analgesic Narcotic drugs (NSAIDs) Acetaminophen (COX-2)
Characteristic OR P value OR P value OR P value OR P value OR P value
Age (per 10 years) 1.03 0.058 0.97 0.26 1.01 0.78 1.13 <0.0001 1.14 0.18
Male (vs. female) 0.77 <0.0001 0.90 <0.0001 0.87 0.23 0.90 0.24 0.93 0.76
African American (vs. other) 1.03 0.65 0.90 0.19 1.36 0.02 1.07 0.44 0.98 0.95
Comorbidities (yes vs. no)
Coronary artery disease 1.07 0.27 1.13 0.11 1.29 0.13 0.92 0.43 1.19 0.54
Cardiovascular diseasea 1.15 0.03 1.21 0.008 0.90 0.50 1.25 0.04 0.67 0.22
Cerebrovascular disease 1.15 0.02 1.07 0.38 1.11 0.54 1.29 0.008 1.17 0.66
Lung disease 1.16 0.03 1.18 0.056 1.49 0.02 1.04 0.71 1.05 0.89
Cancer (other than skin) 1.23 0.02 1.27 0.02 1.31 0.13 0.93 0.56 0.63 0.32
Neurologic disorder 1.08 0.33 1.05 0.58 0.91 0.65 1.26 0.03 0.89 0.83
Psychiatric disease 1.31 <0.0001 1.37 <0.0001 1.10 0.55 1.16 0.13 0.75 0.37
Recurrent cellulitis 1.58 <0.0001 1.73 <0.0001 1.10 0.67 1.16 0.30 1.24 0.71
Time on end-stage renal disease 1.05 <0.0001 1.04 <0.0001 1.08 <0.0001 1.04 0.0009 0.79 0.02
(ESRD) (per year)
Married (vs. other) 0.96 0.46 1.05 0.41 1.08 0.56 0.88 0.15 0.72 0.28
Household income
<$10,000 1.00 0.98 1.14 0.29 0.86 0.47 0.92 0.62 1.33 0.59
$10,000 to $20,000 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
>$20,000 0.76 0.007 0.81 0.12 0.76 0.20 0.78 0.13 2.41 0.07
Geographic region
East North Central 1.15 0.47 0.86 0.50 0.87 0.59 1.40 0.43 0.63 0.33
East South Central 1.13 0.61 1.15 0.51 0.71 0.22 1.08 0.87 0.77 0.64
Middle Atlantic 1.04 0.87 0.58 0.03 0.69 0.17 2.37 0.07 0.08 0.01
Mountain 0.76 0.39 0.71 0.25 0.65 0.33 1.44 0.46 0.42 0.33
New England 0.93 0.79 0.78 0.38 0.46 0.18 1.14 0.81 0.39 0.29
Pacific 0.98 0.93 0.81 0.34 0.92 0.77 0.88 0.79 0.53 0.32
South Atlantic 0.95 0.77 0.94 0.74 0.68 0.09 1.00 0.99 0.81 0.54
West North Central 2.12 0.007 0.21 0.46 1.00 0.99 4.24 0.002 0.16 0.05
West South Central 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Use of narcotic analgesic — — — — 1.48 0.01 1.80 <0.0001 3.44 <0.0001
Use of any nonnarcotic — — 1.88 <0.0001 — — — — — —
aCardiovascular is cardiac disease other than coronary artery disease or congestive heart failure.
CONCLUSION
Our results highlight that analgesics may be underpre-
scribed in the hemodialysis population. With respect to
prevention of chronic kidney damage, the National Kid-
ney Foundation’s position paper suggests acetaminophen
as the nonnarcotic agent of choice for episodic use, al-
though habitual use, and use of combination analgesic
products, should be discouraged [12]. It is possible, al-
though uncertain, that this recommendation has lead to
a more cautious use of analgesics in general in patients
with kidney disease and resulted in potential underpre-
scription. The safest approach to the management of pain
in dialysis patients may be the use of short courses of anal-
gesics, where possible. Extra vigilance is warranted for
potential adverse effects of all analgesics in dialysis pa-
tients. There are few recommendations regarding anal-
gesic use for patients with advanced kidney disease. A
recent review [10] suggests using the clinical practice
guidelines developed by the World Health Organization
for the management of pain in cancer patients [11]. The
extreme variability in facility practice suggests that pa-
tients and clinicians should be educated about the need
to appropriately prescribe analgesics. Patients should un-
derstand that optimal pain management is an acceptable
expectation, and clinicians should examine reasons for
any reluctance on their part to prescribe analgesics. Both
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patients and prescribers should fully understand the suit-
able duration of analgesic therapy. The recent revisions
to the medication use standards of the Joint Commission
on Accreditation of Healthcare Organizations were de-
signed to increase general awareness about many aspects
of drug use [36]. The refinement of existing World Health
Organization guidelines regarding analgesic use in dial-
ysis patients may be necessary to improve pain man-
agement and quality of life for this population. Changes
might be necessary to reflect appropriate choices of anal-
gesics, statements about combination products, and per-
haps education about methods for assessment of appro-
priate analgesia.
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